Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-Like Abcb4-/- mouse model

Digestive Diseases and Sciences

Volumn 58, Issue 5, 2013, Pages 1271-1281

  Mende, Susanne ^a   Schulte, Sigrid ^a   Strack, Ingo ^a   Hunt, Heike ^a,b   Odenthal, Margarete ^a   Pryymachuck, Galyna ^a   Quasdorff, Maria ^a   Demir, Münevver ^a   Nierhoff, Dirk ^a   Dienes, Hans Peter ^a   Goeser, Tobias ^a   Steffen, Hans Michael ^a   Töx, Ulrich ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Abcb4 knockout; AT1R blocker; Beta blocker; Fibrogenesis; Sclerosing cholangitis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; COLLAGENASE 3; CYTOKERATIN 19; ENDOTHELIN 1; HYDROXYPROLINE; MESSENGER RNA; PROCOLLAGEN; PROPRANOLOL; STROMELYSIN; TELMISARTAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT; COMPARATIVE STUDY; CONTROLLED STUDY; FIBROGENESIS; HEPATITIS; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; LIVER HISTOLOGY; MONOTHERAPY; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE; THERAPY DELAY; TREATMENT DURATION; WESTERN BLOTTING;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BILE DUCTS; CHOLANGITIS, SCLEROSING; COLLAGEN TYPE I; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; LIVER; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MYOFIBROBLASTS; P-GLYCOPROTEINS; PROPRANOLOL; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER;

EID: 84878729203     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2499-3     Document Type: Article

References (50)

1. Weismüller T, Wedemeyer J, Kubicka S, Strassburg C, Manns M. The challenges in primary sclerosing cholangitis - aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol. 2008;48:S38-S57.
2. Lindor K, Kowdley K, Luketic V, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808-814.
3. Ramadori G, Veit T, Schwogler S, et al. Expression of the gene of the alpha-smooth muscle-actin isoform in rat liver and in rat fat-storing (ITO) cells. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;59:349-357.
4. Wynn T. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199-210.
5. Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2004;127:261-274.
6. Kawai M, Hongo K, Komukai K, et al. Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats. Hypertens Res. 2009;32:604-610.
7. Naito T, Ma L, Yang H, et al. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. Am J Physiol Renal Physiol. 2009;298:F683-F691.
8. Töx U, Steffen HM. Impact of inhibitors of the renin-angiotensin- aldosterone system on liver fibrosis and portal hypertension. Curr Med Chem. 2006;13:3649-3661.
9. Bataller R, Ginès P, Nicolás J, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000;118:1149-1156.
10. Barki-Harrington L, Luttrell L, Rockman H. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation. 2003;108:1611-1618.
11. Bataller R, Schwabe R, Choi Y, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest. 2003;112:1383-1394.
12. Goebel M, Clemenz M, Unger T. Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan. Expert Rev Cardiovasc Ther. 2006;4:615-629.
13. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens. 2004;22:2253-2261.
14. Nakagami H, Kiomy Osako M, Nakagami F, et al. Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan. Int J Mol Med. 2010;26:477-481.
15. Okunuki Y, Usui Y, Nagai N, et al. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan. Invest Ophthalmol Vis Sci. 2009;50:2255-2261.
16. Wang Z, Xu JP, Zheng YC, et al. Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats. Hepatobiliary Pancreat Dis Int. 2011;10:64-71.
17. Yang L, Stimpson SA, Chen L, Wallace Harrington W, Rockey DC. Effectiveness of the PPARgamma agonist, GW570, in liver fibrosis. Inflamm Res. 2010;59:1061-1071.
18. Oben J, Roskams T, Yang S, et al. Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut. 2004;53:438-445.
19. Atlas S. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13:9-20.
20. Oben J, Roskams T, Yang S, et al. Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice. Biochem Biophys Res Commun. 2003;308:284-292.
21. Dubuisson L, Desmoulière A, Decourt B, et al. Inhibition of rat liver fibrogenesis through noradrenergic antagonism. Hepatology. 2002;35:325-331.
22. Oben J, Roskams T, Yang S, et al. Sympathetic nervous system inhibition increases hepatic progenitors and reduces liver injury. Hepatology. 2003;38:664-673.
23. Strack I, Schulte S, Varnholt H, et al. β-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis. Lab Invest. 2011;91:252-261.
24. Takaya T, Kawashima S, Shinohara M, et al. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis. 2006;186:402-410.
25. Su J, Chen S, Wu K, et al. Effects of perindopril, propranolol, and dihydrochlorothiazide on cardiovascular remodelling in spontaneously hypertensive rats. Zhongguo Yao Li Xue Bao. 1999;20:923-928.
26. Schulte S, Oidtmann A, Kociok N, et al. Hepatocyte expression of angiotensin II type 1 receptor is downregulated in advanced human liver fibrosis. Liver Int. 2009;29:384-391.
27. Stegemann H, Stalder K. Determination of hydroxyproline. Clin Chim Acta. 1967;18:267-273.
28. Batts K, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19:1409-1417.
29. Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud J. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology. 1994;20:349-355.
30. Farazi P, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho R. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 2006;66:6622-6627.
31. Multi-system analysis of physiology on 7 inbred strains of mice. (Database on the Internet) 2011. Cited 20 Jan 2011. Available from: http://phenome.jax.org.
32. Silveira M, Lindor K. Primary sclerosing cholangitis. Can J Gastroenterol. 2008;22:689-698.
33. Kanno K, Tazuma S, Chayama K. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4). Biochem Biophys Res Commun. 2003;308:177-183.
34. Priester S, Wise C, Glaser SS. Involvement of cholangiocyte proliferation in biliary fibrosis. World J Gastroint Pathophysiol. 2010;1:30-37.
35. Trauner M, Fickert P, Baghdasaryan A, et al. New insights into autoimmune cholangitis through animal models. Dig Dis. 2010;28:99-104.
36. Pinzani M, Milani S, De Franco R, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology. 1996;110:534-548.
37. Rockey D, Chung J. Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J Clin Invest. 1996;98:1381-1388.
38. He S, Prasanna G, Yorio T. Endothelin-1-mediated signaling in the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in astrocytes. Invest Ophthalmol Vis Sci. 2007;48:3737-3745.
39. Teerlink J. Reversal of left ventricular remodeling: role of the endothelin pathway. J Card Fail. 2002;8:S494-S499.
40. Schmitt-Gräff A, Chakroun G, Gabbiani G. Modulation of perisinusoidal cell cytoskeletal features during experimental hepatic fibrosis. Virchows Arch A Pathol Anat Histopathol. 1993;422:99-107.
41. -/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol. 2005;43:1045-1054.
42. -/- mice. Hepatology. 2010;51:267-276.
43. Mayoral P, Criado M, Hidalgo F, et al. Effects of chronic nitric oxide activation or inhibition on early hepatic fibrosis in rats with bile duct ligation. Clin Sci (Lond). 1999;96:297-305.
44. Gomes A, Bastos C, Afonso C, Medrado B, Andrade Z. How variable are hydroxyproline determinations made in different samples of the same liver? Clin Biochem. 2006;39:1160-1163.
45. Iredale J, Benyon R, Arthur M, et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology. 1996;24:176-184.
46. Okazaki I, Watanabe T, Hozawa S, Niioka M, Arai M, Maruyama K. Reversibility of hepatic fibrosis: from the first report of collagenase in the liver to the possibility of gene therapy for recovery. Keio J Med. 2001;50:58-65.
47. Steenport M, Khan K, Du B, Barnhard S, Dannenberg A, Falcone D. Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: evidence for the role of TNF-alpha and cyclooxygenase-2. J Immunol. 2009;183:8119-8127.
48. Border W, Noble N. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286-1292.
49. Nakken K, Nygård S, Haaland T, et al. Multiple inflammatory-, tissue remodelling- and fibrosis genes are differentially transcribed in the livers of Abcb4 (-/-) mice harbouring chronic cholangitis. Scand J Gastroenterol. 2007;42:1245-1255.
50. Jin H, Yamamoto N, Uchida K, Terai S, Sakaida I. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient l-amino acid-defined diet. Biochem Biophys Res Commun. 2007;364:801-807.